An anticancer agent, when administered into the body, may exert undesired pharmacological effects also in healthy sites other than the affected site because it circulates through the body.
The company's products are nanoparticles with a controlled diameter smaller than 100 nanometers (or 1000 Angstroms). The core of the nanoparticle is a drug in an inactive form which can subsequently be activated to generate the therapeutic effect.
Nanoarray systems offer a fast, convenient and accurate method for detecting specific chemical or biological entities, particularly related to infectious or toxic molecules such as protein markers.
The company is developing prototype devices for transdermal and pulmonary delivery and would welcome discussions with potential co-development and investment partners with interest in large molecule and vaccine delivery as well as affinity maturation and drug modification.
